Aboriginal and Prisoner HCV Drug Coverage for HOLKIRA PAK™

On September 11th we were notified that AbbVie's new interferon-free hepatitis C treatment for genotype 1, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonovir and dasabuvir [±ribavirin]), is now formally listed by the Non-Insured Health Benefit Program (NIHB) and Correctional Services Canada (CSC). Both have listed HOLKIRA PAK™ in accordance with the Common Drug Review’s recommendations: liver fibrosis stage of ≥2, and treatment should be initiated by physic

US Prisoners get sofosbuvir-simeprevir with new Guidelines

In Canada, we are still awaiting the kind of hepatitis C treatment now recommended for federal prisoners in the USA! New guidelines were just released in May 2014 and are available here: http://www.bop.gov/resources/pdfs/hepatitis_c_current.pdf These are the recommended treatments for federal prisoners with chronic hepatitis C, according to genotype (GT): GT1: PREVIOUS NON-RESPONDER (partial or null) TO INTERFERON TREATMENT or INTERFERON-INTOLERANTcombine